By Fineline Cube 
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX to develop a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). The collaboration aims to advance therapies for metabolic diseases, including weight management, through injectables, oral preparations, and other forms. Financial details of the partnership were not disclosed.
Collaboration Details
iCarbonX has leveraged its artificial intelligence capabilities combined with peptide microarray screening technology to identify a potent GLP-1R/GIPR/GCGR triple agonist. The project has successfully completed the animal efficacy screening phase and has identified a preclinical candidate compound (PCC), marking a significant milestone in the development of this innovative therapy.-Fineline Info & Tech